Press Releases Ligand Pharmaceuticals Incorporated

Equities

LGND

US53220K5048

Real-time Estimate Cboe BZX Other stock markets 08:18:32 08/05/2024 pm IST			5-day change	1st Jan Change
81.04 ^USD	+10.69%		+11.46%	+11.46%

07/05	Transcript : Ligand Pharmaceuticals Incorporated, Q1 2024 Earnings Call, May 07, 2024
07/05	Earnings Flash (LGND) LIGAND PHARMACEUTICALS INCORPORATED Posts Q1 Revenue $31M, vs. Street Est of $27.9M	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Ligand: Q1 Earnings Snapshot	08/05	AQ
Ligand Reports First Quarter 2024 Financial Results	08/05	BU
Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement	07/05	BU
Ligand to Report First Quarter 2024 Financial Results on May 7, 2024	23/04	BU
Ligand Pharmaceuticals Incorporated : Certificate of Incorporation/Bylaws - Form 8-K	20/04	PU
Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference	08/04	BU
Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI	04/04	AQ
Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI™	03/04	BU
Ligand Pharmaceuticals to Present at Barclays 26th Annual Global Healthcare Conference	06/03	BU
Ligand Pharmaceuticals Announces Inducement Grants under Nasdaq Listing Rule 5635(4)	05/03	AQ
Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	04/03	BU
Ligand: Q4 Earnings Snapshot	27/02	AQ
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results	27/02	BU
Ligand Partner Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa®	23/02	BU
Ligand Pharmaceuticals Expands Senior Leadership Team with Two Key Hires	19/02	AQ
Ligand Pharmaceuticals Expands Senior Leadership Team with Two Key Hires	16/02	BU
Ligand to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024	14/02	BU
Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	02/02	BU
Henlius and Sermonix Announce Strategic Collaboration and Exclusive License Agreements for Novel Endocrine Therapy Lasofoxifene	12/01	AQ
U.S. Food and Drug Administration Approves ZELSUVMI™ as a First-in-Class Medication for the Treatment of Molluscum Contagiosum	06/01	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Ligand Pharmaceuticals Incorporated

Equities

LGND

US53220K5048

Press Releases

Filters